Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 55%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health has demonstrated a robust financial trajectory, achieving a 7% year-over-year growth in a challenging competitive environment, primarily through enhancing its data offerings and new partnerships. The company is poised for significant upside driven by the growth of Guardant Reveal in the cancer recurrence monitoring market and the Shield colorectal cancer screening franchise, alongside improvements in reimbursement and guideline inclusions. Guardant Health maintains over 50% market share in its primary segment and is expected to see expanding average selling prices (ASP) and increased test volume, particularly with recent advancements in reimbursement and pricing strategies.

Bears say

Guardant Health's stock outlook is negatively impacted by the high price-to-earnings (P/E) multiple currently valued in the upper half of its multi-year average, which may not be sustainable due to external factors. The company faces significant risks related to reimbursement dynamics that could diminish average selling prices (ASP) and lead to a potential revenue reduction of approximately $100 million if PAMA regulations are implemented. Additionally, uncertainties surrounding the regulatory landscape for multi-cancer early detection (MCED) tests pose challenges that could hinder revenue growth and adoption of Guardant's assays, further straining profitability and future financial performance.

GH has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 55% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 20 analysts, GH has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $118.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $118.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.